Imugene Ltd (IUGNF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The OASIS study, officially titled “A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors,” aimed to test a new cancer virus therapy. It focused on safety, dosing, and early signs of benefit in adults with late-stage solid tumors.
The main treatment was Imugene’s onCARlytics (CF33-CD19), an engineered virus given either into the vein or directly into tumors. It was tested alone or together with the cancer drugs blinatumomab and hydroxyurea to see if the mix could better target and kill solid tumors.
This was an early stage, interventional Phase 1 trial with no placebo group. Patients were assigned to different treatment arms, the study was open-label with no blinding, and the main goal was to check safety and find suitable dose ranges rather than prove full effectiveness.
The trial was first submitted in mid-September 2023, marking the formal start of the program in the clinic. The last update on March 4, 2026, showed the overall status as terminated, which signals that enrollment and treatment have stopped and the focus shifts to data review and interpretation.
For investors, a terminated Phase 1 study usually weighs on sentiment, as it raises questions on safety, dosing, or strategic priorities for Imugene Ltd (IUGNF). It can also slow timelines versus peers in solid tumor immuno-oncology, where larger players and other virus-based therapies are also competing for early proof-of-concept and future partnering deals.
The OASIS trial of onCARlytics has been updated on ClinicalTrials with a terminated status, and further details remain available on the ClinicalTrials portal for investors tracking Imugene’s pipeline outlook and risk profile.
To learn more about IUGNF’s potential, visit the Imugene Ltd drug pipeline page.